Healthcare giant Fresenius SE & Co. KGaA has officially moved to consolidate its position in the rapidly expanding biosimilars market, announcing today that it has acquired the remaining 45% stake in mAbxience from Insud Pharma. The deal marks the transition of the biosimilars firm into a wholly-owned subsidiary, a strategic maneuver that Fresenius describes as the dawn of a “new phase of growth” for its biopharma division.
Fresenius originally established its footprint in the sector by acquiring a 55% majority stake in mAbxience back in August 2022. Since that initial partnership, the platform has been integrated into Fresenius Kabi’s broader Biopharma business, which encompasses the entire life cycle of drug development, from initial manufacturing to global commercialization. By securing 100% ownership, Fresenius aims to streamline operations and leverage the platform’s infrastructure to meet the rising global demand for affordable biologics.
The timing of the acquisition is deliberate, aligning with an impending industry shift as a major wave of high-value biologics prepares to lose patent exclusivity. This “patent cliff” offers a significant opportunity for biosimilar manufacturers to provide lower-cost alternatives to the market.
Michael Sen, CEO of Fresenius, underscored the strategic rationale behind the total buyout. “Full ownership gives us complete control over cost, capacity and launch timing, and full economic benefit, as the next wave of biologics loses exclusivity,” Sen stated. “For patients, that means dependable access to high-quality biosimilars; for shareholders, it is a disciplined investment in a business we know well.”
For mAbxience, the acquisition represents a natural evolution of its existing business model. Jürgen van Broeck, who will continue to lead the company and report directly to Dr. Sang-Jin Pak, President of Biopharma at Fresenius, expressed optimism regarding the company’s future. “Full ownership is the natural next step and creates an even stronger platform for innovation, growth and long-term impact for patients, customers, and partners,” said van Broeck. He noted that the company plans to preserve its foundational entrepreneurial spirit and scientific expertise while scaling its operations under the unified Fresenius umbrella.
The company has moved to reassure its existing network of customers and partners that the transition will not disrupt ongoing operations. mAbxience affirmed that it remains fully committed to its global supply chains and quality standards.
This acquisition is the latest in a series of consolidations within the pharmaceutical industry as major players look to capture market share in the growing biologics sector. By bringing the entirety of the mAbxience platform under its direct control, Fresenius is positioning itself to be a dominant force in providing supply resilience and innovation as the market enters a period of intense competition and transformation.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
